RSV F Protein Purification Yield via Anion Exchange and HIC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current purification methods for recombinantly-produced RSV F proteins result in low overall product yield and inefficient reduction of non-reactive trimer species, while also failing to effectively eliminate residual host cell proteins, which poses safety and efficacy risks.
Innovation Solution
A purification method involving sequential anion exchange chromatography, carbonate-containing hydroxyapatite chromatography, and Hydrophobic Interaction Chromatography (HIC) steps, bypassing cation exchange chromatography, to enhance yield and reduce non-reactive trimer species without compromising the elimination of host cell proteins and bioactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cation exchange chromatography step is used in the purification process, then host cell proteins are effectively removed, but product yield is significantly reduced due to conversion of reactive trimers into non-reactive trimers
Solution Approach 1:
The invention extracts and removes the harmful cation exchange chromatography step from the purification process. By eliminating this step that causes conversion of reactive trimers into non-reactive trimers, the method preserves product yield while maintaining effective removal of host cell proteins through alternative means (anion exchange and HIC steps).
Solution Approach 2:
The invention inverts the traditional chromatography sequence by replacing cation exchange with anion exchange chromatography followed by hydrophobic interaction chromatography. This inverted approach achieves both host cell protein removal and preservation of reactive trimer form, resolving the contradiction between purity and yield.
2Reliability
If conventional chromatography steps are used, then host cell proteins are minimized, but non-reactive trimer species are not effectively reduced
Solution Approach 1:
The invention applies local quality by using hydrophobic interaction chromatography with specific wash conditions (pH 7.0-8.0, high salt concentration) that selectively target and remove non-reactive trimer species while preserving reactive trimers. This localized optimization of chromatography conditions achieves precise separation based on the different properties of reactive versus non-reactive forms.
3Manufacturing precision
If multiple chromatography steps are implemented, then product purity is enhanced, but process complexity and time are increased
Solution Approach 1:
The invention merges the functions of multiple chromatography steps into a streamlined sequence of three main steps (anion exchange, HIC, and final polishing). By combining and optimizing these steps, the method achieves high product purity while reducing overall process complexity and time compared to conventional multi-step protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method increases product yield from 5-10% to 20-40% and effectively eliminates non-reactive trimer species, maintaining the stability and bioactivity of the purified RSV F proteins.
Implementation Method 1
contacting a load solution comprising the RSV F protein with an anion exchange chromatography medium, whereby the RSV F protein binds to the anion exchange chromatography medium; washing the anion exchange chromatography medium with at least one lower pH wash solution at a pH between 3.0 and 6.5; and eluting the RSV F protein from the anion exchange chromatography medium
Implementation Method 2
a Hydrophobic Interaction Chromatography (HIC) step
Data Source
AI summary
The invention relates to a purification method of a recombinantly-produced RSV F protein in trimeric form. According to the invention, the method sequentially comprises an anion exchange chromatography step, a cHA chromatography step and a HIC step. The invention is also directed to a pharmaceutical product including an RSV F protein purified by such a method.